NeuroPace Business Summary

NeuroPace Inc. (NPCE) is a commercial-stage medical technology company that generates revenue primarily through the sale of its proprietary RNS (Responsive Neurostimulation) System, the first and only FDA-approved brain-responsive platform for treating drug-resistant focal epilepsy. The company's business model is centered on product sales to Level 4 epilepsy centers, with a core revenue segment driven by the implantation and replacement of its closed-loop neurostimulators. As of early 2026, NeuroPace has streamlined its operations by terminating its distribution partnership with DIXI Medical to focus exclusively on its high-margin RNS portfolio, which is projected to drive $98–$100 million in 2026 revenue. In the competitive landscape of neuromodulation, NeuroPace competes directly with Medtronic (Deep Brain Stimulation), LivaNova (Vagus Nerve Stimulation), and Boston Scientific. Unlike its competitors' scheduled stimulation devices, NeuroPace occupies a unique market niche as the sole provider of a personalized, "closed-loop" system that monitors brain activity in real-time and delivers stimulation only when seizure patterns are detected. The company was founded in 1997 by the Fischell family and is currently led by CEO Joel Becker, who joined in 2023 with extensive experience from leadership roles at Integer Holdings and St. Jude Medical. The executive team includes Patrick F. Williams as Chief Financial Officer (appointed June 2025), a veteran of STAAR Surgical and NuVasive, and Brett Wingeier as VP of Research and Development, a former co-founder of Magnus Medical who was a principal engineer during the RNS System's initial development. Marketing efforts are led by VP Katie Keller, formerly of Boston Scientific. The company is chaired by long-time former CEO Frank Fischer, with a board of directors that includes high-profile members such as Joseph S. Lacob (CEO of the Golden State Warriors) and R. Scott Huennekens (former CEO of Verb Surgical). Major institutional backing is provided by Accelmed Partners, OrbiMed Advisors, and Soleus Capital, supporting the company's strategic expansion into new indications like idiopathic generalized epilepsy.